{"id":945390,"date":"2026-03-18T09:06:19","date_gmt":"2026-03-18T13:06:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/"},"modified":"2026-03-18T09:06:19","modified_gmt":"2026-03-18T13:06:19","slug":"pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/","title":{"rendered":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting"},"content":{"rendered":"<h2>\nSelected for oral presentation at Clinical Trials Mini Symposium<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., March  18, 2026  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.<\/p>\n<p>The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium.<\/p>\n<p>\n        <strong><br \/>\n          <u>Oral Presentation<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title:<\/strong>\u00a0First-in-human phase I study of PLN-101095, a first-in-class dual \u03b1<sub>v<\/sub>\u03b2<sub>8<\/sub>\/\u03b1<sub>v<\/sub>\u03b2<sub>1<\/sub>integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI)<\/p>\n<p>\n        <strong>Presenter:\u00a0<\/strong>Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center<br \/><strong>Session:<\/strong>\u00a0CTMS01: Updates in Anticancer Immunotherapies<br \/><strong>Date: <\/strong>Saturday, April 18, 2026<br \/><strong>Presentation Time: <\/strong>10:21 a.m. &#8211; 10:31 a.m. Pacific Time <br \/><strong>Location: <\/strong>Ballroom 6A &#8211; Upper Level \u2013 San Diego Convention Center<\/p>\n<p>\n        <strong><br \/>\n          <u>Oncology\u00a0Program<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>PLN-101095 is an oral, small molecule, dual selective inhibitor of \u03b1v\u03b28 and \u03b1v\u03b21 integrins designed to overcome checkpoint resistance by blocking TGF-\u03b2 activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a\/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with\u00a0<em>pembrolizumab<\/em>, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors.<\/p>\n<p>\n        <strong>About Pliant Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company\u2019s lead program is PLN-101095, a small molecule, dual-selective inhibitor of \u03b1v\u00df8 and \u03b1v\u00df1 integrins, that is being developed for the treatment of solid tumors. Pliant\u2019s early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ONhjCfHiqHcrJPk1Qq1E8cd0BCQs7teGWXhKgjadWFWjsRQfXzclfWiDtAJPDkkjqxiBrOWJv2UNdmKVshy_-w==\" rel=\"nofollow\" target=\"_blank\"><u>www.PliantRx.com<\/u><\/a>. Follow us on social media <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QgCge_-o_4iwy4uTmc88iyu5oJL9rgk84O_XftF9pfHBNXEjz_qn0368kkit305EALMylYMthDuETStig4SL6A==\" rel=\"nofollow\" target=\"_blank\"><u>X<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZuRqVl2xSEGJNXqe0MNxeBjfcateyQSQoQqRBuFi_KA6UNrnhT5r-7Z7SsnzxdAuTvmiFfBKwCBftRzoHRgBt-a_o3ccgDdnfBruECNU_mo=\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pfP6TQFGGOV2nUAPVUo7T5v4jZk4aUy7rSxeTY8e8AsfI7f3nF_iUgVjm7KcLnVBEsye9BBSiiDLlh5mBFqGo9mNwr35FlhgoajjQH8ngBg=\" rel=\"nofollow\" target=\"_blank\"><u>Facebook<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong>\n      <\/p>\n<p>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cJMle4k3RYDCT2wdNh7sVOjbkg6-HwZedG_tYzb7BySquwg0z7G2NF_uZEgyLiKvSA5sws_QKHbfZHGfHLeDO7wCoV9WRtMeMOafkwMkQt8=\" rel=\"nofollow\" target=\"_blank\">ir@pliantrx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjcwZGVhYzQtNGEyNS00NjYwLTljMDctMWE1N2RlMDcxOTZlLTExOTcwMzAtMjAyNi0wMy0xOC1lbg==\/tiny\/Pliant-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Selected for oral presentation at Clinical Trials Mini Symposium SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title:\u00a0First-in-human phase I study of PLN-101095, a first-in-class dual \u03b1v\u03b28\/\u03b1v\u03b21integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI) Presenter:\u00a0Timothy A. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-945390","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Selected for oral presentation at Clinical Trials Mini Symposium SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title:\u00a0First-in-human phase I study of PLN-101095, a first-in-class dual \u03b1v\u03b28\/\u03b1v\u03b21integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI) Presenter:\u00a0Timothy A. &hellip; Continue reading &quot;Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T13:06:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting\",\"datePublished\":\"2026-03-18T13:06:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/\"},\"wordCount\":360,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/\",\"name\":\"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\",\"datePublished\":\"2026-03-18T13:06:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk","og_description":"Selected for oral presentation at Clinical Trials Mini Symposium SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title:\u00a0First-in-human phase I study of PLN-101095, a first-in-class dual \u03b1v\u03b28\/\u03b1v\u03b21integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI) Presenter:\u00a0Timothy A. &hellip; Continue reading \"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-18T13:06:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting","datePublished":"2026-03-18T13:06:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/"},"wordCount":360,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/","name":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=","datePublished":"2026-03-18T13:06:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NDIwOCM3NDkxMzQ2IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-announces-upcoming-presentation-of-phase-1-clinical-trial-of-pln-101095-in-patients-with-solid-tumors-at-the-2026-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=945390"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/945390\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=945390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=945390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=945390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}